Su1088 Participation in Decision Making Increases Patients' Adherence to Therapy in Ulcerative Colitis

Kruis, Wolfgang; Mroß, Michael; Kahl, Matthias; Toermer, H.J.; Deuster, Uwe H.; Reimers, B.

doi:10.1016/s0016-5085(14)61337-8

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tablet preference over granules was also reported by MacKenzie-Smith et al [15]. Granule preference was reported in the German MUKOSA study, where patients expressed a marked preference for granules (77%) over tablets (13%) [13], and in two other studies, patients with UC reported that the granules have higher acceptability than tablets [18,19].…”

Section: Discussionmentioning

confidence: 56%

“…In addition, pharmaceutical formulation prescription according to patient preference may have a positive impact on adherence to treatment and consequently on treatment outcomes. It appears concordant that prescribing the patient-preferred formulation may lead to a better adherence to treatment [10][11][12][13][14]. MacKenzie-Smith et al [15] reported that patients with UC generally prefer tablets with a lower daily pill burden as well as fewer daily intakes.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Medication Formulation Preference of Mild and Moderate Ulcerative Colitis Patients: a European Survey

Hébuterne¹,

Vavricka²,

Thorne³

et al. 2023

Inflamm Intest Dis

View full text Add to dashboard Cite

Introduction: Patient adherence is a major challenge for the successful management of any chronic disease, and ulcerative colitis (UC) is no exception. Patient adherence is closely related to patient preference of medication and formulation used. Aim: The aim of this study was to investigate patient and physician perspectives around UC treatment preference. Methods: This study was conducted in France, Germany, Spain, and the UK. Physicians and UK inflammatory bowel disease (IBD) nurses answered an online questionnaire. In addition, adult mild-to-moderate UC patients, treated with oral mesalazine, were invited to answer a 30-min online survey which included a conjoint exercise. Results: 400 patients, 160 physicians, and 20 IBD nurses participated in the survey. 68% of patients were taking tablets and 32% granules. Physicians stated that from their perspective patients are more adherent to tablets than granules (76% vs. 24%), patients tended to have better relief of symptoms with tablets (69% vs. 31%), and patients found tablets to be the most convenient formulation (61% vs. 39%). From the patients’ perspective, when questioned which formulation they prefer, 58% answered tablets, 37% granules, and 5% none of these. When patients were asked about some negative attributes of tablets, the highest agreement was for “I would like to take fewer each day” (6.1/10) and “I wish I could take fewer at a time” (5.4/10). Conclusions: The majority of UC patients in this survey prefer the tablet formulation. A high strength tablet overcoming the high pill burden could be a good solution to address patient expectations.

show abstract